Clinical Trials Logo

Clinical Trial Summary

Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is an immune mediated life-threatening disease. There is no uniform recommendation for salvage treatment of HLH. Based on the results of current clinical trials, the marketing situation of the drug in China, and the use requirements of pegylated recombinant human granulocyte stimulating factor(PEG-rhG-CSF), this study was conducted in patients who received the DEP rescue therapy or dexamethasone combined with VP-16 maintenance therapy. The aim of this study was to evaluate the efficacy and safety of PEG-rhG-CSF(Jinyouli®) for the recovery of neutropenia after chemotherapy in patients with hemophagocytic syndrome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04500886
Study type Interventional
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Zhao Wang, PHD
Phone 86-1063139862
Email catenny@hotmail.com
Status Not yet recruiting
Phase N/A
Start date August 1, 2020
Completion date September 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT04999878 - A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. Phase 4
Recruiting NCT05882175 - Prospective Validation of the OHI Index
Not yet recruiting NCT05353179 - Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Early Phase 1
Completed NCT02113917 - Children and Adult Hemophagocytic Syndrome (HLHa)
Recruiting NCT05936086 - A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH N/A